Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04187404 · ClinicalTrials.gov registry record · Phase 1
A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma
A Phase 1 study, sponsored by Enterome.
- Terminated
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
NCT04187404 is a Phase 1 study that was terminated before completion, run by Enterome. The registered enrollment target is 70 participants.
The verdict
NCT04187404, a Phase 1 study, was terminated before completion, sponsored by Enterome.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
Study Summary
This is a multicenter, Phase 1/2, First-In-Human study to assess the safety, tolerability, immunogenicity, and preliminary efficacy of EO2401 in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma.
Interventions
- BIOLOGICAL Nivolumab
- BIOLOGICAL EO2401
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2020-07-23 |
| Est. Completion | 2024-10-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04187404
The ClinicalTrials.gov registry entry for NCT04187404 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Enterome, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nivolumab is the first listed.
NCT04187404 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04187404 about?
NCT04187404 is a clinical study titled "A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma". This is a multicenter, Phase 1/2, First-In-Human study to assess the safety, tolerability, immunogenicity, and preliminary efficacy of EO2401 in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma.
What is the current status of trial NCT04187404?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2020-07-23. Estimated completion is 2024-10-02.
What interventions are being tested in trial NCT04187404?
The interventions under investigation include: Nivolumab (BIOLOGICAL), EO2401 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04187404?
This trial is sponsored by Enterome, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.